Tuesday, May 12, 2015

Now distributing the tremoFlo P-100 for pre-clinical research

All of us at emka TECHNOLOGIES & SCIREQ are excited to announce that we have partnered with THORASYS Thoracic Medical Systems Inc. to offer the tremoFlo P-100, a highly detailed and reproducible Airway Oscillometry System (AOS) for lung function testing in large animals.

About the tremoFlo

The tremoFlo AOS is a portable lung function testing instrument that can measure respiratory mechanics in large animals (dogs, NHPs) non-invasively. The system comprises a lightweight handheld device attached to a cradle unit. Subjects breathe directly into the handheld unit during measurements via a disposable anti-bacterial/viral filter and a subject mask. The tremoFlo software provides subject management, testing and result interpretation capabilities.

The tremoFlo system provides detailed, physiologically-relevant endpoints of lung obstruction (resistance) and stiffness (reactance), as well as other advanced parameters related to lung heterogeneities, respiratory rate, tidal volume, dynamic collapse, and central vs. peripheral airway effects for spontaneously breathing subjects. These outcomes are translational and clinically-relevant in applications such as:

  • Respiratory assessment for safety and toxicology studies using dogs and NHP models
  • Demonstrating compliance with ICH guidelines
  • Studying the off-target effects
  • Integrating safety endpoints to existing toxicology studies
  • Drug efficacy and validation studies
  • Exploratory toxicology, cross-reactivity studies, and more!

    Offering a complete range of respiratory solutions

    As recognized leaders in pre-clinical science, emka TECHNOLOGIES and SCIREQ have helped scientists uncover novel insights into disease mechanisms and evaluate therapeutic approaches that target the respiratory, cardiovascular and neurological functions. We are proud to add the tremoFlo P-100 to our list of respiratory solutions used to enhance your research.

    Contact us

    Phone 1.514.286.1429 | Toll Free 1.877.572.4737
    Email sales@scireq.com

    Learn more about the tremoFlo P-100 for pre-clinical lung function testing at www.scireq.com/non-invasive/tremoflo

    Learn more about THORASYS and the tremoFlo C-100 for lung-function assessment in patients (clinical application) at www.thorasys.com

  • 5 reasons to stop by our booth at ATS

    The American Thoracic Society's annual international conference is just a few days away and we look forward to meeting with industry leaders and learning what's new in the field of respiratory research.

    Here are just a few of the many reasons to stop by the emka & SCIREQ booth #428 at ATS this year:

    1. See the range of emka & SCIREQ products that cover your respiratory research needs from cell and tissues to isolated organs and in vivo models

    2. Learn about lung volumes and how you can add RV and TLC measurements to your list of outcomes

    3. Meet with our application specialists and staff scientist to discuss your new projects

    4. See the tremoFlo, a unique tool to perform conscious measurements in large subjects

    5. Get all the details on how to attend our Breakfast Symposium on respiratory drug development with speakers Dr.Phillips and Dr.Lewis

    Schedule

    Sunday May 17     Exhibit hall: 10:30am to 5pm
    Monday May 18     Breakfast Symposium: 7am (click here for details & to register!)
                                   Exhibit hall: 10:30am to 5pm
    Tuesday May 19   Exhibit hall: 10:30am to 3pm

    Contact us
    Phone 1.514.286.1429 | Toll Free 1.877.572.4737
    Email sales@scireq.com

    Monday, May 4, 2015

    World Pulmonary Hypertension Day

    "The heart and lungs are intricately related. Whenever the heart is affected by disease, the lungs will follow, and vice versa. Pulmonary heart disease is by definition a condition when the lungs causes the heart to fail."

    American Medical Network

    Pulmonary hypertension can develop from diseases that affect millions of people including sleep apnea, scleroderma, sickle cell disease, HIV, chronic obstructive pulmonary disease (COPD), schistosomiasis, hereditary hemorrhagic telangiectasia (HHT), liver disease and lupus.

    On May 5th, join us in raising awareness about this fatal disease affecting over 25 million people worldwide.

    PH by the Numbers

    Symptoms of PH are often mistaken for those of less serious conditions, such as asthma.

    Many patients spend 2-3 years seeking an accurate diagnosis.

    Delay in diagnosis can be fatal; without treatment, the average life expectancy with PH is 2.8 years.

    Many patients will see 3 or more different physicians over a 3 year period before they are properly diagnosed with PH.

    To learn more about how to raise awareness, please visit: www.worldphday.org.


    Pre-clinical Research

    See how emka TECHNOLOGIES and SCIREQ provide a wide range of solutions for preclinical pulmonary and cardiovascular research.

    www.sallyosborne.com/StudentPresentations/PulmonaryHypertension.pdf
    www.scireq.com/flexivent/applications#cardio
    cardiovascular.emka.fr